A Swiss Cross-Sectional Study on Patients’ Perspectives on Chronic Pain Management, Analgesic Treatment, and Genetic Susceptibility
This study provides the first large-scale, representative insights into the use of PGx actionable drugs and treatment patterns in Swiss chronic pain care. In particular, the high prevalence of PGx actionable drug use and the strong patient interest in genetic information support not only the clinical, but also the biopsychosocial potential of PGx for chronic pain management.
Authors
- Samuel Allemann (ORCID: https://orcid.org/0000-0003-4067-9401)
- Anna Bollinger (ORCID: https://orcid.org/0000-0003-4616-2534)
- Henriette E. Meyer zu Schwabedissen (ORCID: https://orcid.org/0000-0003-0458-4579)
- Céline K. Stäuble (ORCID: https://orcid.org/0000-0002-2437-4803)
- Isabelle O. Urdieux
Institutions
- University of Basel (CH)
- Stadtspital Waid (CH)
Publication Details
- Journal
- Journal of Pain Research
- Published
- 2025-09-01
- DOI
- https://doi.org/10.2147/jpr.s543460
- Primary Topic
- Pain Management and Opioid Use
- Type
- article
- Field-Weighted Citation Impact
- 0.00